相关实验视频

Updated: May 12, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

拉泽提尼布与奥西默提尼布在以前未经治疗的EGFR突变高级NSCLC中:来自MARIPOSA的随机,双盲,探索性分析

Se-Hoon Lee¹, Shun Lu², Hidetoshi Hayashi³

¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

|July 5, 2025

概括

拉泽提尼布在晚期NSCLC患者中显示出与奥西默提尼布相似的疗效和安全性. 这种对第三代EGFR TKIs的比较发现了可比的无进展生存率和反应率.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

拉泽提尼布是一种第三代EGFRTKI,由于野生类型EGFR毒性较低,因此被选为组合疗法.
马里波萨研究表明,在未经治疗的EGFR突变先进NSCLC中,使用阿米万他马布加拉泽提尼布对奥西默提尼布的无进展生存率 (PFS) 得到了改善.
纳入了拉泽提尼布单一治疗臂,以评估其个体贡献.

研究的目的:

为了比较拉泽提尼布单疗法与奥西默提尼布单疗法的疗效和安全性.
评估拉泽提尼布作为组合疗法的组成部分的作用.

主要方法:

在MARIPOSA研究中,有1074名参与者被随机选择.
参与者接受了阿米万塔-拉泽提尼布,奥西默提尼布单疗法或拉泽提尼布单疗法,比例为2:2:1.
这项分析主要集中在拉泽提尼布和奥西梅提尼布单一治疗手臂.

主要成果:

中位数的PFS是可比的:拉泽提尼布18.5个月与奥西默提尼布16.6个月 (HR=0.98,p=0.86).
客观反应率为拉泽提尼布的83%,奥西梅提尼布的85%.
副作用主要是1-2级,而拉泽提尼布的QT间隔延长率较低.

结论:

拉泽提尼布的疗效和安全性与奥西默提尼布相当.
这些发现在预定义的子组中是一致的.
拉泽提尼布为EGFR突变高级NSCLC提供了与奥西默提尼布相似的替代方案.

关键词:

在EGFR突变的NSCLC中.第一线治疗是第一线治疗.拉泽蒂尼布 (Lazertinib) 是一种药物.奥西默蒂尼布 (Osimertinib) 是一种药物.铁氨酸激酶抑制剂铁氨酸激酶抑制剂

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...